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encephalitogenic Th1 T cells and B cells during
experimental autoimmune encephalomyelitis
Petra D Cravens1†, Bernd C Kieseier2†, Rehana Hussain1†, Emily Herndon3, Benjamine Arellano1, Li-Hong Ben1,
Brenda C Timmons4, Cyd Castro-Rojas1, Hans-Peter Hartung2, Bernhard Hemmer5, Martin S Weber5,6,7,
Scott S Zamvil8,9* and Olaf Stüve1,2,5,10*Abstract
Multiple sclerosis (MS) is thought to be a CD4+ T cell mediated autoimmune demyelinating disease of the central
nervous system (CNS) that is rarely diagnosed during infancy. Cellular and molecular mechanisms that confer
disease resistance in this age group are unknown. We tested the hypothesis that a differential composition of
immune cells within the CNS modulates age-associated susceptibility to CNS autoimmune disease. C57BL/6 mice
younger than eight weeks were resistant to experimental autoimmune encephalomyelitis (EAE) following active
immunization with myelin oligodendrocyte glycoprotein (MOG) peptide (p) 35–55. Neonates also developed milder
EAE after transfer of adult encephalitogenic T cells primed by adult or neonate antigen presenting cells (APC). There
was a significant increase in CD45+ hematopoietic immune cells and CD45+ high side scatter granulocytes in the
CNS of adults, but not in neonates. Within the CD45+ immune cell compartment of adults, the accumulation of
CD4+ T cells, Gr-1+ and Gr-1- monocytes and CD11c+ dendritic cells (DC) was identified. A significantly greater
percentage of CD19+ B cells in the adult CNS expressed MHC II than neonate CNS B cells. Only in the adult CNS
could IFNγ transcripts be detected 10 days post immunization for EAE. IFNγ is highly expressed by adult donor CD4
+ T cells that are adoptively transferred but not by transferred neonate donor cells. In contrast, IL-17 transcripts
could not be detected in adult or neonate CNS in this EAE model, and neither adult nor neonate donor CD4+ T
cells expressed IL-17 at the time of adoptive transfer.
Keywords: Age, Antigen presentation, Autoimmunity, Development, EAE, Experimental autoimmune
encephalomyelitis, Human, Lymphocytes, Major histocompatibility complex, MHC, MS, Mouse, Multiple sclerosis,
Rodent, T helper cells 17Introduction
Multiple sclerosis (MS) is the most common inflamma-
tory demyelinating disorder of the central nervous sys-
tem (CNS) in humans with a presumed autoimmune
pathogenesis [1]. A first-time diagnosis of MS is exceed-
ingly rare during early childhood [2,3]. To date, the
youngest patient reported with physician-diagnosed MS
was 24 months old at the time of the initial clinical* Correspondence: zamvil@ucsf.neuroimmunol.org; olaf.stuve@
utsouthwestern.edu
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reproduction in any medium, provided the orattack [4]. The youngest reported patient with acute de-
myelinating encephalomyelitis (ADEM), a self-sustained
monophasic CNS autoimmune disease following an
acute infection or immunization, was 15 months old [5].
Cellular or molecular mechanisms that confer relative
disease resistance during infancy are unknown.
Activated myelin-reactive CD4+ Th1 cells are thought to
have a central role in the pathogenesis of MS, and its
prototypic animal model experimental autoimmune en-
cephalomyelitis (EAE) [6]. CD4+ T cells are activated
through recognition of linearized peptides presented in the
context of major histocompatibility complex (MHC) II on
antigen (Ag) presenting cells (APC) [7,8]. Ag presentation
in the context of MHC II appears to be required atl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suggested that the activation of T cells in secondary lymph-
oid organs facilitated their entry into the brain and spinal
cord [9,10] but more recently, it was shown that CNS-
specific T cells can enter the CNS without the requirement
for antigen priming in peripheral lymphoid tissues [11].
While healthy CNS tissue is devoid of MHC II protein ex-
pression, circulating APC, including myeloid cells and B
lymphocytes that have entered the perivascular spaces or
parenchyma of the CNS from the peripheral blood consti-
tutively express MHC II. After CNS injury, astrocytes
[12,13] and microglial cells [14,15] can also upregulate
MHC II in response to inflammatory mediators, including
IFNγ, the signature cytokine of T helper 1 (Th1) cells [16].
MHC II-mediated Ag presentation results in reactivation
of CD4+ T cells, and an amplified immune response [17].
Thus, the regulation and expression of MHC II genes are
considered critical in MS and its animal model, EAE.
We utilized both the active immunization and adop-
tive transfer models of EAE to test the hypothesis that a
differential composition of immune cells within the CNS
modulates age-associated susceptibility to CNS auto-
immune disease.
Materials and methods
Peptides
Mouse myelin oligodendrocyte glycoprotein peptide
(MOGp) 35–55 [MEVGWYRSPFSRVVHLYRNGK] was
synthesized by solid-phase Fmoc chemistry by QCB, Inc.
(Hopkinton, MA, USA) and CS Bio (Menlo Park, CA,
USA).
Animals
C57BL/6 and B10.PL wild-type (wt) mice were pur-
chased from the Jackson Laboratory (Bar Harbor, ME,
USA). Vα2.3/Vβ8.2 TCR-transgenic mice provided by Dr
Joan Goverman were bred in a specific pathogen-free fa-
cility at the University of Texas (UT) Southwestern. All
protocols involving mice handling were approved by the
UT Southwestern animal care facility.
Induction of experimental autoimmune encephalomyelitis
To induce active EAE, C57BL/6 female mice were immu-
nized subcutaneously with MOGp35-55 emulsified in an
equal volume of complete Freund adjuvant (CFA) (DIFCO
Laboratories, Detroit, MI, USA) in each flank. Mice were
4 days, 1, 2, 3, 4, 5, 6, 7, 8, and 20 weeks of age. Immedi-
ately after the immunization, and again 48 hours later,
mice received an intravenous injection of pertussis toxin
(Ptx) in PBS. All animals received an equivalent dose of
Ag, adjuvants, and Ptx on a dose per weight basis: Per 20
g bodyweight, 100 μl of vaccine, containing 100 μg
MOGp35-55 and 2 mg/ml mycobacterium, as well as 400
ng Ptx were administered.For the induction of EAE by adoptive transfer, spleens
from either 2-week-old or 8-week-old Vα2.3/Vβ8.2
TCR-transgenic mice [18], were removed and single-cell
suspensions were prepared. Splenocytes were cultured in
24-well plates at 1 × 106 cells/well with wt B10PL adult or
neonatal irradiated splenocytes (3K Rads) at a ratio of 1:4.
The cells were cultured in Roswell Park Memorial Insti-
tute (RPMI) medium 1640 with 10% FCS and stimulated
with 6µg/ml myelin basic protein (MBP)Ac1-11 and 0.5ng/
ml IL-12 in a 24-well plate for 72 hrs. Cells were washed
with PBS and injected intraperitoneally (i.p.) into naive
B10PL, adult (5 × 106/200 µls) or neonatal (1 × 106/50
µls) mice. Two independent experiments were conducted
with a minimum of ten mice per group.
For all EAE experiments, individual animals were ob-
served daily and clinical scores were determined as fol-
lows: 0 = no clinical disease, 1 = loss of tail tone, 2 = mild
paraparesis, 3 = paraplegia, 4 = hindlimb and forelimb
paralysis, 5 = moribund or death. Three independent ex-
periments were conducted with a minimum of five mice
per group.
Proliferation assays
Splenocytes (5 × 105 cells/well) from mice that had been
immunized with MOGp35-55 10 days prior to sacrifice,
were cultured in the presence of MOGp35-55 in RPMI
1640, supplemented with 5 × 10-5 M 2-mercaptoethanol,
2 mM glutamine, 100 μg/ml penicillin, 100 μg/ml
streptomycin, 10% FCS (HyClone, Logan, UT, USA).
After 72 hrs of culture, cells were pulsed with 1 μCi
(3H)-thymidine and harvested 16 hrs later.
For assessment of Ag presentation by APC of various
ages, splenocytes were γ-irradiated (33 Gy), and plated
at 5 × 105 cells/well with 1 × 104 MOGp35-55-specific
CD4+ T cells, and increasing doses of MOGp35-55. For
generation of MOGp35-55-specific T cells, spleens were
removed 0 to 14 days after immunization, and
splenocytes were cultured in the presence of MOGp35-55
(25 μg/ml) and IL-2 (25 IU q3d). Every 14 days, T cells
were washed, counted, and re-stimulated with APC and
Ag for a minimum of three times. The purity of CD4+ T
cells was analyzed by flow cytometry prior to each ex-
periment, and approached 95% (data not shown). Cul-
tures were pulsed with (3H) thymidine at 48 hrs and
harvested 16 hrs later. The mean cpm ± SD of (3H) thy-
midine incorporation was calculated for triplicate
cultures.
B cell adoptive transfer experiments
CD19+ B cells were negatively sorted by magnetic
separation (Stem Cell Technologies, BC, Canada) with
a purity of >85% from spleens of 8- to 12-week-old
donor mice that had been actively immunized for
EAE with 50 µg of mouse rMOG in CFA 10 days
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B cells were transferred i.p. into 4-day-old neonates
and 5 × 106 B cells into 8-week-old adult recipients.
At this time recipient mice were immunized with
CFA/MOGp35-55. A week later, 3 × 10
6 B cells from
adult donors immunized as described above were
transferred i.p. to both neonates and adult recipients.
Mice were monitored daily for clinical signs of dis-
ease as described previously.
In vitro T helper cell differentiation
Splenocytes were prepared from naïve 2- and 8-week-old
mice and CD4+CD62L+ T cells were sorted on the
FACSAria (purity was > 98%). In vitro polarization of T
cells (0.25 × 106 cells/well in 2ml complete RPMI) was
done in 24-well plates coated with anti-CD3 (1 mg/ml)
and anti-CD28 (10 mg/ml) (BD Biosciences, San Jose, CA,
USA) as previously described [19]. For T cell polarization
RPMI was supplemented as follows: 2 mg/ml anti-IFN-γ
(R46A2) for Th0, 5 ng/ml IL-12 for Th1, 10 ng/ml IL-4,
and 5 mg/ml anti-IFNγ for Th2 and 25 ng/ml IL-6, 0.5
ng/ml TGF-β, 10 ng/ml IL-1β and 10 ng/ml TNF-α for
Th17. On day 3 cells were split into fresh antibody-coated
plates and 1 ml of fresh RPMI supplemented with cyto-
kines was added to the appropriate wells: 10 U/ml IL-2
and 2 μg/ml anti-IFNγ (R46A2) for Th0, 10 U/ml IL-2
and 5 ng/ml IL-12 for Th1, 10 ng/ml IL-4 for Th2 and 25
ng/ml IL-6, 0.5 ng/ml TGF-β, 10 ng/ml IL-1β and 10 ng/
ml TNF-α for Th17. At 48 and 72 hrs of the second
stimulation culture supernatants were collected and cyto-
kine ELISA performed as described below. All monoclonal
antibodies (mAb) and cytokines were purchased from R &
D Systems (Minneapolis, MN, USA).
Enzyme-linked immunosorbent assay
Cell culture supernatants from experiments described
above were collected at 48- and 72-hr time points for
cytokine analysis as previously described [9,10]. Quantita-
tive ELISA for IL-17 and IFNγ was performed using
paired mAb specific for corresponding cytokines as per
manufacturer’s recommendations (BD Biosciences or
R&D Systems). The results of ELISA assays are expressed
as an average of triplicate wells ± SD. The SOFTmax
ELISA plate reader and software was used for data analysis
(Molecular Devices Corporation, Sunnyvale, CA, USA).
Flow cytometry
Mice were perfused via the left ventricle with cold PBS
and brains, spinal cords, and spleens were harvested. Tis-
sues were pressed through a 70-μm nylon mesh cell
strainer. Splenocytes were treated with RBC lysing buffer
(Sigma-Aldrich, St. Louis, MO, USA). CNS cells from all
mice in each experimental group were pooled and
processed as previously described [11]. In brief, CNS cellswere washed twice in 37% Percoll and CNS mononuclear
cells were isolated by centrifugation at 2118 × g for 15 mi-
nutes at 22°C, over a 30/70% Percoll gradient. The inter-
phase cells were collected, washed with 0.5% BSA/PBS,
re-suspended in complete RPMI 1640, and counted. For
flow cytometry, the following mAb were used: anti-
CD3-Pacific Blue (500A2), anti-B220-PE (RA3-6B2), anti-
CD11c-APC (HL3), anti-Gr1-APC-Cy7 (RB6-8C5), all
from BD Biosciences; anti-CD11b PerCp-Cy5.5 (M1/70),
anti I-Ab PE-Cy5 (M5/114-152), anti-CD45-PE-Cy7 (30-
F11), anti-CD19-Alexa Fluor 700(1D3), biotinylated anti-
pan NK (DX5), all from eBiosciences (San Diego, CA,
USA); anti-CD4-PE-Texas Red (MCD0417) and anti-CD8
-Pacific Orange (MCD0830), both from Invitrogen (Grand
Island, NY, USA); and biotinylated anti-PDCA-1 from
Miltenyi (Auburn, CA, USA). Biotinylated mAb were re-
vealed with SA-Q Dot 655 from Invitrogen. Cells were re-
suspended in staining buffer (4% FCS and 0.1% sodium
azide in PBS) and Fc receptors blocked with anti-CD16/32
(BD Biosciences) for 15 minutes at 4°C before staining
with mAb for 30 minutes at 4°C. Cells were washed, re-
suspended in staining buffer, and fixed in 1% paraformal-
dehyde. Up to 500,000 events were acquired on a
FACSAria (BD Biosciences) and analyzed using FlowJo
software (Tree Star, Ashland, OR, USA).
RNA isolation and quantitative real-time PCR (QRT-PCR)
Neonatal and adult animals were sacrificed on day 10 post
immunization with CFA/MOGp35-55. Following 1.5%
Avertin overdose (400 mg/kg for adults), animals were
transcardially perfused with 20 ml ice cold PBS and the
CNS was removed. Total RNA was extracted from CNS
homogenates using standard techniques [20]. Taqman
gene expression assays and the Step One Plus (Applied
Biosystems, Foster City, CA, USA) were used to detect
IFNγ, IL-10, IL-12 and IL-23. Relative gene expression be-
tween unimmunized mice (naïve) and mice immunized
for EAE was determined using the ddCT method (Applied
Biosystems User Bulletin #2). The dCt was normalized to
the housekeeping gene ribosomal 18s rRNA, and the ddCt
was normalized to the average of the naïve neonatal CNS
dCts.
Ki-67 staining
Ki-67 staining was performed to determine the number
of proliferating cells in the CNS. Following fixation in
10% formalin, brains and spinal cords from naïve and im-
munized mice were serially sectioned. Tissues were em-
bedded in paraffin, cut at 4 μm thickness, mounted on
Fisher Brand Superfrost Plus glass slides, and stained
with H&E (Fisher Scientific, Pittsburgh, PA, USA).
Deparaffinization and staining with rabbit monoclonal
Ventana anti-Ki-67 clone 30–9 was performed on the
Ventana Benchmark XT automatic immunostainer with
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trieval system (Ventana Medical Systems, Tucson, AZ,
USA). The antibody was used at a concentration of 2 μg/
ml, and immunoreactivity was detected with Ultraview
horseradish peroxidase/diaminobenzidine. For analysis,
the percentage of Ki-67-immunoreactive cells was calcu-
lated for selected mice using a Glasgow cell-counting
graticule at 20× magnification with a Nikon Labophot-2
at a magnification of 20×. The thalamus location was
chosen for analysis to avoid counting proliferating neuro-
glial precursors present in brains of immature mice. Ten
fields were quantified for each mouse, and the mean was
used for comparison.
Confocal microscopy
Following fixation in 4% paraformaldehyde for at least 2
hrs, tissues were stored in 2% sucrose at 4°C until cut-
ting. The brains were coronally sectioned and after em-
bedding in Tissue-tek OCT Compound, the tissues were
snap frozen in liquid nitrogen. Two 6 μm-thick sections
were cut from each brain with a freezing microtome and
mounted on Fisherbrand Superfrost Plus glass slides
(Fisher Scientific, Pittsburgh, PA, USA). Tissue sections
were then fixed in 10% formalin and rinsed in tap water.
One set of tissues was stained with H&E and prepared
for light microscopy, and the other set was prepared
without staining for fluorescent microscopy. Areas of
interest were captured on digitized images using a Leica
TCS SP5 confocal microscope with the 63× objective and
analyzed by ImageJ 1.35s software (public domain; http://
rsbweb.nih.gov/ij/).
Statistical analysis
All experiments were repeated at least twice. Correla-
tions between continuous and categorical variables were
assessed using the Mann-Whitney U-test. The means of
two normally distributed samples were compared by
Student t-test. All other statistical comparisons between
groups were examined using one-way multiple range
analysis of variance (ANOVA) for multiple comparisons
or Student-Newman-Keuls multiple comparison test. A
P-value <0.05 was considered significant. Data are given
as mean ± standard error.
It is generally accepted that 10 mice per treatment
group are required to test the effect of reagents in ac-
tive immunization EAE. This number was determined
through power analysis. Through testing the null hy-
pothesis (that the mean disease severity will be equal
among the two treatment groups), it is possible to attain
>80% power with the following assumptions: the criter-
ion for significance (alpha) has been set at 0.050; the test
is two-tailed, which means that an effect in either direc-
tion will be interpreted; this computation assumes that
the mean difference is 1.7 (corresponding to mean EAEscores of 1.7 versus 0.0; or 2 versus 3.7) and the com-
mon intra-group SD is 1.0. This minimum significant
difference of 1.7 was selected from prior observations
that repeatable effects were associated with changes in
mean disease score of between 1.5 and 2.0. Thus, this
work assumes that effects smaller than 1.7 would not be
of clinical or substantive significance and that differences
in mean clinical score of 1.7 can be anticipated. A sec-
ond goal of this study was to estimate the mean differ-
ence between the two populations. On average, a study
of this design would enable us to report the mean differ-
ence with a precision (95.0% confidence level) of plus/
minus 1.13 points. For example, an observed difference
of 1.7 between treatment groups would be reported with
a 95.0% CI of 0.57 to 2.83. The precision estimated here
is the median precision. Precision will vary as a function
of the observed SD (as well as sample size), and in any
single study will be narrower or wider than this estimate.
All analyses were performed with Prism 5 for Windows
(Graphpad, La Jolla, CA, USA).Results
Susceptibility to experimental autoimmune encephalitis is
age-associated
To examine age-associated susceptibility to CNS auto-
immune disease, EAE was induced in C57BL/6 mice be-
tween the ages of 4 days and 20 weeks by immunization
with MOGp35-55. Animals younger than 8 weeks were re-
sistant to EAE (Figure 1A). There was no difference with
regard to disease severity between 8-week-old and 20-
week-old mice (Figure 1A), but both these groups were
significantly different from mice younger than 8 weeks.The age of APC contributes to recall proliferative
responses in vitro
Since Ag-specific CD4+ T cell responses depend on inter-
action with MHC II molecules expressed on APC, T cell
responses were initially assessed with primary prolifera-
tion assays. The 12-day-old splenocytes failed to proli-
ferate in response to Ag, whereas the proliferative
responses in splenocytes from 8-week-old mice were ro-
bust (Figure 1B). In order to determine whether absent
proliferative responses of immature splenocytes were due
to deficiencies in the APC or T cell compartment, irradi-
ated, naive splenocytes of different ages were used to
present MOGp35-55 to a MOGp35-55-specific T cell line that
had been generated from mature mice. At 48 hrs, de-
creased proliferative responses were observed at low and
intermediate Ag doses when presented by APC from 12-
day-old mice (Figure 1C). This relative deficiency in Ag
presentation by APC from 12-day-old mice could be com-
pensated with high doses of Ag (Figure 1C).
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Figure 1 Age-dependent disease susceptibility to experimental autoimmune encephalomyelitis. (A) C57BL/6 mice (H-2b) between the
ages of 4 days and 20 weeks were immunized with myelin oligodendrocyte glycoprotein (MOG)p35-55 to actively induce experimental
autoimmune encephalomyelitis (EAE). Animals younger than 8 weeks were resistant to EAE. There was no difference in disease severity between
8- and 20-week-old mice, but both these groups are significantly different from mice younger than 8 weeks. (B) Age-associated capability of
splenocytes to present antigen. The 10-day-old splenocytes fail to proliferate in response to antigen (Ag), whereas the proliferative responses in 8-
week-old mice are robust. (C) Decreased proliferative responses are also observed when gamma-irradiated splenocytes from 10-day-old mice
present MOGp35-55 at low and intermediate doses to MOGp35-55-specific T cells. This relative deficiency in Ag presentation by irradiated
splenocytes from 10-day-old mice can be compensated with high doses of Ag.
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encephalitogenic T cells
An adoptive transfer model employing Vα2.3Vβ8.2 TCR
transgenic mice on the B10.PL background (H-2u) was uti-
lized to examine the relative contribution of MHC II-
restricted Ag presentation in the periphery and CNS on
age-associated EAE susceptibility. In a first set of experi-
ments, donor cells from adult Vα2.3Vβ8.2 TCR transgenic
mice were primed in vitro with irradiated splenocytes from
neonatal or adult B10.PL mice, and transferred into neo-
natal or adult recipients (Figure 2A and B). Adult recipi-
ents developed clinical disease earlier and more severely
than neonatal recipients in both settings (Figure 2A and
B). However, there was no difference in disease activity be-
tween neonatal or adult mice that received adoptively
transferred adult CD4+ T cells primed by neonatal or adult
APC in vitro (Figure 2A and B), indicating that neonatal
APC in secondary lymphoid organs are generally capable
of generating encephalitogenic T cells in the presence of
high Ag concentrations. Similarly, adult recipients of adult
CD4+ Vα2.3Vβ8.2 T cells co-cultured with either neonatal
or adult APC developed clinical disease earlier and more
severely than neonatal recipients (data not shown).The cellular composition of leukocytes within the CNS is
age-associated
To investigate the contribution of age to development of
CNS autoimmunity, CNS from neonates (4 days old) and
adult mice (6 to 8 weeks old) that had been immunized
for EAE 10 days previously was examined for the pre-
sence of immune cells by multiparameter flow cytometry
(Figure 3). Three populations of common leukocyte anti-
gen CD45+ cells were identified in the CNS using side
scatter (SSC) analysis (Figure 3A), Gr-1+ granulocytes
(R1), CD11b+ myeloid and CD11b- lymphoid immune
cells (R2) and CD45dim microglial cells (R3). A significant
increase in CD45+ hematopoietic immune cells and CD
45+ high SSC granulocytes was detected in the CNS of
adults but not in neonates (Figure 4A and B). In fact, a
significant decrease in the number of CD45+ hem-
atopoietic cells occurred in the neonate CNS post
immunization (P = 0.0009). This observed decrease was
consistent within the CD45+ CNS lymphocyte population
(gating strategy shown in Figure 3C) of neonates
(Figure 4C), with a significant decrease in CD4+ and CD8+
T cells (p<0.0001), CD19+ B cells (p=0.0461) and DX5+
NK cells (P = 0.0005) after immunization for EAE. By
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Figure 2 Experimental autoimmune encephalomyelitis (EAE) disease course in adult mice is more severe than in neonates. Adult and
neonatal B10.PL recipient mice received 5 × 10 [6] (adults) or 1 × 10 [6] (neonates) adult Vα2Vβ8 transgenic T lymphocytes that had been
re-stimulated in vitro for 72 hrs in the presence of MBPAc1-11 peptide prior to adoptive transfer. Clinical scores shown are from at least two
independent experiments. Error bars represent ± SD.
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cantly increased by day 10 post immunization (P = 0.0135)
(Figure 4D). Within the myeloid cell compartment (gating
strategy shown in Figure 3B) (Figure 4E and F), a signifi-
cant decrease in Gr-1-CD11b+ monocytes (P <0.0001) and
CD11c+ DC (P = 0.0058) was detected in neonatal CNS.
The numbers of Gr-1+CD11b+ monocytes within the neo-
natal CNS were not impacted by immunization for
EAE. In adults both Gr-1- (P = 0.0088) and Gr-1+CD11b+
(P = 0.0134) monocytes and CD11c+ DCs (P = 0.0113)
were significantly elevated post immunization. A direct
comparison of cells/g of CNS in the immunized neonatal
CNS versus immunized adult (Figure 5A) showed that
CD4+ T cells as well as CD8+, CD19+, DX5+ NK, Gr-
1+CD11b+ and Gr-1-CD11b+ monocytes, CD11c+ DC
and pDC fail to accumulate in the neonatal CNS. The
numbers of CD45+−HSSC granulocytes and CD45dim
microglia in the neonatal and adult CNS were not
statistically different at day 10 post immunization
(Figure 5B).
The increased number of Gr-1+CD11b+ monocytes in the
neonatal CNS is not due to proliferation within the CNS
Since the numbers of all other immune cells examined in
the neonatal CNS decreased at day 10 post immunization
and only Gr-1+CD11b+ monocytes remained constant, we
examined neonatal and adult CNS for expression of Ki-67Ag to determine whether local expansion of immune cells
contributed to the apparent accumulation within the adult
CNS (Figure 6A). Consistent with our observations using
flow cytometry, Ki-67 staining decreased two-fold (from
8.2% to 4.9%) in the neonatal CNS post immunization,
whereas there was an increase in Ki-67 positive cells in
the adult CNS (0.2% to 1.3%). These results indicate that
proliferation within the CNS contributes to the accumula-
tion of immune cells.
To examine more specifically the effect on myeloid cell
numbers in situ in the CNS after immunization with
CFA/MOGp35-55, neonatal and adult CX3CR1
GFP/+mice
in which cells of the myeloid lineage, including microglia,
are GFP+ [21], were evaluated by confocal microscopy for
GFP-expressing myeloid cells in naïve and immunized
animals (Figure 6B). The results of two individual mice
(M1 and M2) per treatment group are shown. While the
presence of Ki-67+ cells was decreased in the immunized
neonates, the numbers of GFP+ cells observed in the CNS
at day 10 post immunization remained stable in neonatal
and adult mice.
The differential cellular expression of MHC II is age-
associated
Since MHC II-mediated Ag-presentation results in re-
activation of CD4+ T cells upon entry into the CNS, we
examined CNS APC subsets from immunized neonatal
Figure 3 (See legend on next page.)
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Figure 3 Gating strategy to identify CD45+ hematopoietic immune cells that have accumulated in the central nervous system (CNS) of
neonates and adult mice prior to onset of experimental autoimmune encephalomyelitis (EAE). (A) At day 10 post immunization with
complete Freund adjuvant (CFA)/ myelin oligodendrocyte glycoprotein (MOG)35-55, neonatal and adult mice were perfused and CNS cells isolated
and prepared for flow cytometry. Cells were examined by side scatter (SSC) versus CD45 staining and three populations of CD45+ cells were
identified; R1, CD45+ high SSC cells, which were Gr-1+ and represent granulocytes; R2, CD45+ hematopoetic immune cells, which were further
divided into CD11b+ myeloid cells and CD11b- non-myeloid cells containing lymphocyte subsets; and R3, CD45dim microglia, which dimly express
CD11b. Results are representative of three independent experiments. (B) Antigen-presenting cells (APC) within the CD45+CD11b+ cell population
were identified by expression of Gr-1 to identify Gr-1+ monocytes, Gr-1- monocytes, and CD11c+ DC. Histograms on the right represent staining
for major histocompatibility complex (MHC) II using anti-I-Ab. (C) T cells were identified in the CD45+CD11b- fractions by expression of CD3, CD4
and CD8. CD19+ B cells and DX5+ NK cells were identified in the CD45+CD11b-CD3- fraction. Plasmacytoid dendritic cells (PDC) were identified in
the CD45+CD11b-CD3- by expression of B220 or PDCA1.
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differences in median fluorescence intensity (MFI) of
MHC II staining were not statistically significant between
neonates and adults for any of the APC subsets examined
(Figure 7A). The percentage of CD19+ B cells thatCe
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Figure 5 Immune cells accumulate in the adult but not in the neonatal central nervous system (CNS) post-immunization with
complete Freund adjuvant (CFA)/myelin oligodendrocyte glycoprotein (MOG)p35-55. The number of CNS mononuclear cells/g of CNS from
neonates (gray bars) and adults (black bars) are directly compared (A). There were significantly more CD45+ immune cell subsets in the adult
versus the neonatal CNS by day 10 after immunization for experimental autoimmune encephalomyelitis (EAE).
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Figure 6 Central nervous system (CNS) Ki-67 nuclear proliferation antigen counterstained with hematoxylin. (A) Proliferating cells in the
CNS of naive and immunized neonatal (top panels) and adult mice (bottom panels) are indicated by red circles (magnification ×20). (B) Analysis
of naive and immunized neonatal and adult CNS by confocal microscopy. Circles indicate GFP+ cells. The results shown are examples of two
individual mice (M1 and M2) per treatment group (magnification ×63). There was no significant change in the numbers of GFP+ cells between
naive and immunized mice in either age group.
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http://www.jneuroinflammation.com/content/10/1/67-CD11b+ monocytes (top panels) and CD19+ B cells (bot-
tom panels) is shown in panel C. Treatment of MS pa-
tients with B cell-depleting therapies has revealed a role
for B cells in the pathogenesis of MS.
Since neonates immunized for EAE did not accumulate
B cells in the CNS by day 10 post immunization and the
percentage of neonate B cells expressing MHC II mole-
cules was significantly reduced as compared to immunized
adults, we examined whether EAE would develop in neo-
nates if they received adoptively transferred B cells from
immunized adults. Adult and neonatal C57BL/6 mice
were immunized for EAE as described above. At days 3
and 10 post immunization CD19+ B cells were transferred
i.p. and disease was followed for 25 days (data not shown).
Adult animals developed EAE at day 12 post im-
munization, whereas neonates did not. Transfer of B cells
isolated from immunized donors did not alter the onset of
EAE nor disease severity suggesting that B cells areMHC II
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The inflamed adult but not neonatal CNS promotes a Th1
environment
To determine whether there is a difference between neo-
nates and adult mice in the cytokines present in the CNS
at day 10 post immunization and before disease onset, total
RNA was isolated from the CNS and real time PCR
performed (Figure 8A, B). Immunized adults but not
immunized neonates expressed IFNγ at day 10 post
immunization with CFA/MOGp35-55 (Figure 8A). The rela-
tive gene expression for IL-12 (Figure 8B) was also signifi-
cantly higher in the CNS of immunized adult mice than
neonates. IL-10 and IL-17 transcripts were not detected in
neonates or adults (data not shown). Therefore the neo-
natal CNS remains un-inflamed after immunization
through a mechanism that does not involve IL-10.Adult
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sion is IFNγ, which is expressed by CD4+ T cells, CD8+ T
cells, natural killer (NK) cells, and natural killer T (NKT)
cells. The source of IFNγ in EAE is likely activated CD4+
T cells, as the disease is induced through antigen presenta-
tion of MHC II-restricted Ag. To examine whether the T
cells from neonates have the potential to differentiate into
Th effector populations that contribute to CNS auto-
immunity in adult mice, highly purified CD4+CD62L+
naive T cells from neonates and adults were differentiated
in vitro in the presence of either Th1- or Th17-inducing
conditions. Supernatants were collected at 48 hrs and 72
hrs and the levels IFNγ and IL-17 were determined by
ELISA. In vitro, neonatal CD4+ T cells were as capable as
adult CD4+ T cells of producing IFNγ under Th1E
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To quantify IFNγ expression in neonatal and mature en-
cephalitogenic CD4+ T cells, lymph node cells were pre-
pared for adoptive transfer as described above [22], and
IFNγ expression was determined by ELISA assay after 24,
48, and 72 hrs in culture. At all time points, adult CD4+ T
cells expressed significantly more IFNγ than neonatal
CD4+ T cells (Figure 8E).
Discussion
Several age-associated mechanisms have been proposed to
explain the low disease incidence of MS in infants. Previ-
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rodents [23]. As immune responses against myelin
autoantigens, including myelin basic protein (MBP) [24]
and MOG [25], may be critical in MS pathogenesis, the
formation of the myelin sheath around CNS axons may be
an absolute requirement for CNS autoimmunity to occur.
Even though CNS myelination in mice is completed at age
3 weeks, incomplete CNS myelination would not explain
the results of our study, as neonates develop EAE after the
adoptive transfer of encephalitogenic T lymphocytes.
It also has to be considered that the ascertainment of
MS incidence and prevalence in very young infants is
substantially more complex than in adolescents and
adults. Among the most common clinical signs and
symptoms in adult MS patients are fatigue, imbalance,
pain, cognitive impairment, sexual and bladder dysfunc-
tion, and weakness [26]. It appears difficult, if not impos-
sible, to detect some of these symptoms in infants under
the age of two years.
In this study we show that neonatal mice are resistant to
EAE and that this observed decrease in susceptibility is
not associated with an absolute inability of neonatal T cells
to develop into the Th1 and Th17 effector under opti-
mized in vitro conditions. In light of our observations that
neonatal peripheral APC acted as weaker APC both for
proliferation of a differentiated T cell line, as well as for
differentiation of naive T cells into IFNγ producing Th1
cells, it appears important to note that these data do not
exclude that differences in peripheral APC compartments
may contribute to EAE resistance of younger mice. Re-
gardless, our findings highlight that resistance to EAE is
primarily associated with a relative failure to accumulate
immune cells within the CNS after immunization with
CNS Ag, and immediately prior to disease onset. Specific-
ally, we found that in contrast to the adult CNS where the
numbers of CD4+ lymphocytes, granulocytes and myeloid
APCs, such as Gr-1+ and Gr-1- monocytes, and CD11c+
DC are increased by day 10 after immunization, in the
neonatal CNS all lymphocyte and most myeloid subsets
examined were significantly decreased. The numbers of
granulocytes and Gr-1+ monocytes were unaffected after
immunization.
Interestingly, no significant difference with regard to
MHC II expression was observed between neonatal and
adult mice in any CNS APC population other than CD19+
B cells. The number of CD19+ B cells that expressed
MHC II in immunized adults was significantly higher
compared to that in neonate B cells. This is an intriguing
observation, as there is accumulating evidence that indi-
cates that myelin-specific B cells and myelin-specific anti-
bodies may have important roles in the pathogenesis of
MS. A humoral component in MS has been implicitly rec-
ognized for decades [27-29], evidenced by inclusion of
cerebrospinal fluid (CSF) oligoclonal bands and increasedintrathecal immunoglobulin (Ig) G synthesis in MS diag-
nostic criteria [30,31]. Antibody deposition and immune
complement activation associated with vesicular disinte-
gration of the myelin membrane is present in most MS le-
sions [25,32,33], and autoantibody responses against many
Ags can also be detected in the CSF of many MS patients
[34]. B lymphocytes, of course, are much more than pre-
cursors of plasma cells and are very capable of presenting
Ag to T cells [35]. The unique aspect of B cells as APCs
derives from the expression of the high-affinity B cell re-
ceptor, which recognizes soluble, intact Ags. In addition,
secretion of Fc receptor binding antibodies by activated B
cells promotes opsonization and leads to enhanced APC
function by DC. Adoptive transfer of B cells from adult
donor mice immunized with rMOG did not increase dis-
ease susceptibility in neonatal recipients. Given that the
autoantigen in this experiment was a linear peptide, it is
quite possible that the majority of the transferred B cells
were not antigen-specific.
We demonstrate that in the animal model of MS, EAE
cannot be induced with a standard induction protocol in
otherwise susceptible mice that are below a certain age.
The results of our study are supported by published
work by Massa et al., who showed that the degrees of
EAE susceptibility in different strains of rats correlates
with the quantity of MHC II expression within the CNS
[36]. Specifically, it was demonstrated that fully suscep-
tible Lewis rats (RT-1b) express much higher levels of
MHC II in the CNS than fully resistant Brown Norway
rats (RT-1n) [36]. This observation could be reproduced
in EAE-susceptible SJL mice (H-2s) and EAE-resistant
Balb/c mice (H-2d) [36], which indicates that this
phenomenon may be of critical importance in determin-
ing susceptibility to CNS autoimmune disease in other
mammalian species. Neither one of the prior two publi-
cations determined the cellular sources of MHC II ex-
pression within the CNS. Our group had previously
demonstrated that Ag processing and presentation
within the CNS is an absolute requirement for suscepti-
bility to CNS autoimmune disease [37].
As mentioned above, B lymphocytes constitutively ex-
press MHC II. The MHC II transactivator (CIITA) is con-
sidered the master regulator of MHC II expression [38].
Although CIITA promoter III is viewed as the hema-
topoietic-specific promoter of CIITA, recent findings
demonstrate that promoter IV is active in B lymphocytes
and potentially contributes to the expression of CIITA
and MHC II in these cells [39]. Thus, expression of IFNγ
by T cells likely results in significant upregulation of MHC
II by B lymphocytes. At day 10 after immunization, real
time PCR revealed that the relative expression of IL-12
and IL-23 in both the neonatal and adult CNS was low.
Transcripts for IL-10 were absent in the neonatal and
adult CNS (data not shown). By contrast, the relative
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adults, but not in neonates, by day 10 after active im-
munization with CFA/MOGp35-55. The presence of IFNγ
transcripts in the CNS immediately prior to disease onset
may suggest that (1) peripherally activated CD4+ T cells
are the main provider of this cytokine, and (2) IFNγ plays
a critical role in the activation of local APCs and in the in-
duction of MHC II on these cells, including on B cells.
Overall, the Th1 environment is likely permissive for
the reactivation of encephalitogenic Th1 lymphocytes
that continue to migrate into the CNS from the periphe-
ral blood.
We wanted to test the hypothesis that a differential
composition of immune cells within the CNS modulates
age-associated susceptibility to CNS autoimmune dis-
ease. The interpretation of investigation has some limita-
tions. In essence, there are at least two compartments
that determine susceptibility to CNS autoimmunity: (1)
secondary lymphoid organs, where T cell activation in
the context of an MHC II-restricted Ag presentation, as
well as bystander activation of other immune systems
occurs, and (2) the CNS itself, where re-activation of T
cells and chemoattraction of other immune cells takes
place. Many of our experiments were conducted in ac-
tive EAE. In this model, immunophenotyping allows us
to determine the composition of immune cells in differ-
ent compartments during different ages. One disad-
vantage of this model is that specific pathogenic
mechanisms that lead to a certain cellular composition
can only be speculated upon. The adoptive transfer EAE
model dissects the role of antigen-specific T cells and
APC of different age groups in the periphery in suscepti-
bility to CNS autoimmune disease. In this model, the re-
quirement for T cell re-activation within the CNS is
reduced. The disadvantage of the adoptive transfer EAE
model is the focus on antigen-specific CD4+ T cells,
whereas the role of other immune cells in the periphery
and the CNS is less clear. Thus, with regard to the hu-
man disease MS, the adoptive transfer EAE model
appears even more artificial than active EAE. In addi-
tion, there are experimental and ethical challenges in
conducting true neonatal adoptive transfers into adult
recipients, as T cells at age 16 days already assume char-
acteristics of adult cells.
In summary, our data suggest that the neonatal CNS
is less conducive to autoimmunity than the adult CNS.
As the EAE model that was utilized in our experiments
uses an MHC II-restricted myelin autoantigen to induce
disease, the differential numbers of MHC II-positive B
cells in the brains of neonatal and adult mice is intri-
guing. While our data are not entirely conclusive in this
regard, they provide a rationale for a mechanism to ex-
plain the decreased risk of developing CNS autoimmune
disease at an early age.Abbreviations
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